First Biotherapeutics (CEO Jae-Eun Kim, hereinafter referred to as First Bio) and Moffitt Cancer Center, a global cancer research and treatment institution, have entered into a strategic partnership. The two companies will jointly promote translational research and the development of tumor infiltrating lymphocyte (TIL) cell therapy, along with accelerating the global clinical development of First Bio’s next-generation immunotherapy drug FB849.
FB849, currently undergoing phase 1 clinical trials in the United States, is an innovative new drug candidate that inhibits HPK1 (hematopoietic progenitor kinase 1). Unlike existing immunotherapy anticancer drugs, FB849 shows a differentiated mechanism of action that exerts its anticancer effects not only through T cells but also through various immune cells. Based on FB849’s high target selectivity and superior safety, the company expects that this substance will become the best drug in the HPK1 inhibitor series.
The two companies will accelerate the clinical development of FB849 based on a long-term collaboration that continues to late-stage clinical trials and explore new possibilities for anticancer treatment. After securing clinical proof-of-concept (PoC) data by evaluating the efficacy and safety of specific cancers such as renal cell cancer, they will conduct intermediary research using patient samples. Furthermore, they will conduct related research and clinical trials with the Mophit research team that led the FDA’s first TIL cell therapy approval, and through this, they plan to present more effective treatment options to patients.
“Mofit is committed to building leading partnerships to prevent and treat cancer,” said Xavier Avat, Chief Commercial Officer of Mofit Cancer Center. “This collaboration with FirstBio is an important opportunity to advance innovative research into clinical solutions for a wide range of cancers. FB849 has the potential to be a key therapeutic agent in the treatment of solid tumors, and our collaboration will accelerate the development of this promising candidate.”
“The development of FB849 will open up new possibilities in the field of cancer treatment,” said Jae-Eun Kim, CEO of FirstBio. “This partnership demonstrates our commitment to addressing unmet medical needs in the field of oncology.” He also emphasized, “Through our collaboration with Mofit, we will get one step closer to improving the quality of life for patients around the world.”
- See more related articles
You must be logged in to post a comment.